Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes
This study has been completed.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
First received: July 10, 2003
Last updated: February 23, 2015
Last verified: January 2015
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||March 2008|
|Primary Completion Date:||March 2008 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||August 13, 2010|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Rother KI, Spain LM, Wesley RA, Digon BJ 3rd, Baron A, Chen K, Nelson P, Dosch HM, Palmer JP, Brooks-Worrell B, Ring M, Harlan DM. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care. 2009 Dec;32(12):2251-7. doi: 10.2337/dc09-0773.